Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 7/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | BAX | Q07812 | 2/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569835 | 0.89 | HSD17B2 (0.43) | PPARGPPARDPPARAHSD17B2BAX | |
| SCHEMBL5399381 | 0.88 | PPARA (0.47) | PPARGPPARDPPARAHSD17B2HSD17B1 | |
| SCHEMBL5386585 | 0.88 | PPARA (0.47) | PPARGPPARDPPARAHSD17B2HSD17B1 | |
| SCHEMBL3952266 | 0.87 | HSD17B2 (0.40) | PPARGPPARDPPARAHSD17B2BAX | |
| SCHEMBL3944558 | 0.86 | AOC3 (0.41) | PPARGPPARDPPARAHSD17B2BAX | |
| SCHEMBL3949725 | 0.85 | HSD17B2 (0.38) | PPARGPPARDPPARAHSD17B2BAX | |
| SCHEMBL3946840 | 0.84 | ABHD6 (0.41) | PPARGPPARDPPARAHSD17B2BAX | |
| SCHEMBL3951398 | 0.84 | CARM1 (0.38) | PPARGPPARDPPARAHSD17B2BAX | |
| SCHEMBL3949723 | 0.84 | HSD17B2 (0.40) | PPARGPPARDPPARAHSD17B2BAX | |
| SCHEMBL3955465 | 0.83 | AOC3 (0.44) | PPARGPPARDPPARAHSD17B2BAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285568-B2 | Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-23 | — | — | US | claimed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | claimed |
| EP-1567509-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-08-31 | — | — | EP | claimed |
| WO-2004048351-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-10 | — | — | WO | claimed |
| US-7582663-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2008-03-20 | — | — | US | disclosed |
| US-7285568-B2 | Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-23 | — | — | US | disclosed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | disclosed |
| EP-1567509-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048351-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PPARG 1/4885PPARD 3/4885PPARA 2/4885 |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PPARG 1/4885PPARD 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.